Drug Trial Radar · NCT06142188
Relmacabtagene Autoleucel in Hematologic Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 28, 2023
Primary completion
Dec 31, 2038
Study completion Dec 31, 2038
Sponsor
- Lead sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Conditions
- Lymphoma, B-Cell
- Large B-cell Lymphoma
- Follicular Lymphoma
Interventions
Relmacabtagene AutoleucelBiological
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 15 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking University International Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.